Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
US-10160738-B2 · Dec 25, 2018 · US
US9562026B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9562026-B2 |
| Application number | US-201414203678-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 11, 2014 |
| Priority date | Mar 14, 2013 |
| Publication date | Feb 7, 2017 |
| Grant date | Feb 7, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure is generally directed to neuroactive substituted cyclopent[a]anthracenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
Opening claim text (preview).
What is claimed is: 1. A compound of Formula (I): or a pharmaceutically acceptable salt thereof; wherein: R 1 is H, R 2 is H, R 3 is H, ═O, ═CHCN, ═CHCO 2 R t , where R t is optionally substituted C 1 -C 4 alkyl, optionally substituted C 2 -C 4 alkenyl, or optionally substituded C 2 -C 4 alkynyl, —CN, β-OH, β-OR s , where R s is optionally substituted C 1 -C 4 alkyl, optionally substituted C 2 -C 4 alkenyl, or optionally substituted C 2 -C 4 alkynyl, β-NO 2 , spiroepoxy, or C(O)R r , where R r is optionally substituted C 1 -C 4 alkyl, optionally substituted C 2 -C 4 alkenyl, or optionally substituted C 2 -C 4 alkynyl; R 4 is methyl; R 5 is H, R 6 is H, R 7 is H, R 8 is H, R 9 is H, optionally substituted C 1 -C 4 alkyl, optionally substituted C 2 -C 4 alkenyl, optionally substituted C 2 -C 4 alkynyl, or optionally substituted aryl; R 10 is H, R 11 is H or C(O)R e , where R e is optionally substituted C 1 -C 20 alkyl, optionally substituted C 2 -C 20 alkenyl, or optionally substituted C 2 -C 20 alkynyl; and, - - - denotes an optional double bond with the proviso that when present R 3 is not ═O, ═CHCN or ═CHCO 2 R t . 2. The compound of claim 1 , wherein R 11 is H. 3. The compound of claim 1 , wherein R 3 is ═O. 4. The compound of claim 1 , wherein R 3 is spiroepoxy. 5. The compound of claim 1 , wherein R 3 is β-CN. 6. The compound of claim 1 , wherein a double bond is present between C 2 -C 3 . 7. The compound of claim 6 , wherein R 3 is —CN. 8. The compound of claim 1 , having the structure (I-a): wherein R 3 is ═O, ═CHCN, ═CHCO 2 R t , where R t is optionally substituted C 1 -C 4 alkyl, optionally substituted C 2 -C 4 alkenyl, or optionally substituted C 2 -C 4 alkynyl, —CN, β-OH, β-OR s , where R s is optionally substituted C 1 -C 4 alkyl, optionally substituted C 2 -C 4 alkenyl, or optionally substituted C 2 -C 4 alkynyl, β-NO 2 , spiroepoxy, or C(O)R r , where R r is optionally substituted C 1 -C 4 alkyl, optionally substituted C 2 -C 4 alkenyl, or optionally substituted C 2 -C 4 alkynyl; and, - - - denotes an optional double bond, with the proviso that when present, R 3 is not ═O, ═CHCN or ═CHCO 2 R t . 9. The compound of claim 1 having the structure: or a pharmaceutically acceptable salt thereof. 10. The compound of claim 1 having the structure: or a pharmaceutically acceptable salt thereof. 11. The compound of claim 1 having the structure: or a pharmaceutically acceptable salt thereof. 12. The compound of claim 1 having the structure: or a pharmaceutically acceptable salt thereof. 13. A pharmaceutical composition comprising the compound of claim 1 , a pharmaceutically acceptable salt thereof, or a combination of two or more thereof, and a pharmaceutically acceptable carrier. 14. A method of inducing anesthesia in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.
containing only six-membered rings · CPC title
containing four condensed rings · CPC title
a keto group being part of a condensed ring system · CPC title
by free hydroxyl radicals · CPC title
a keto group being part of a condensed ring system · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.